Kornimate/medical-research-clean huggingface dataset:
collection of circulating biomarkers in pancreatic cancer

Conditions: Pancreas Cancer

Summary: this protocol will involve collection of blood samples from patients with a diagnosis of pancreatic adenocarcinoma for evaluation of circulating biomarkers.


Eligibility criteria:
inclusion criteria: * the subject must have a known or presumed diagnosis of pancreatic adenocarcinoma * the subject must be a patient of the university of pennsylvania * the subject must be able to provide informed consent * the subject must be 18 years of age or older exclusion criteria: . subjects who have any clinically significant psychiatric, social, or medical condition that, in the opinion of the investigator, could increase the patient's risk, interfere with protocol adherence, or affect the patient's ability to give informed consent are ineligible to participate in the study.
5 fractions of pelvic sabr with intra prostatic sabr

Conditions: Prostate Cancer

Summary: stereotactic ablative radiation(sabr) 35 gy in 5 fractions, once weekly to prostate with simultaneous intraprostatic boost to the mr detected nodule up to 50gy + 25 gy in 5 fractions, once weekly simultaneously to seminal vesicles (sv's) and pelvic lymph nodes + 6-18 months of adt

sabr 25gy / 5 fractions to pelvis; 35gy / 5 fractions to prostate; up to 50gy / 5 fractions to mr nodule

Eligibility criteria:
inclusion criteria: * histologically confirmed prostate adenocarcinoma (centrally reviewed) * high- tier intermediate risk defined as: psa 10-20ng/ml and (t2b-2c or gleason 7 ) • high-risk prostate cancer, defined as at least one of: t3, or gleason 8-10, or psa \> 20 ng/ml * willing to give informed consent to participate in this clinical trial * able and willing to complete expanded prostate index composite (epic) questionnaire exclusion criteria: * prior pelvic radiotherapy * contra-indication to radical prostate radiotherapy e.g. connective tissue disease or inflammatory bowel disease * contraindication to prostate mri * anticoagulation medication (if unsafe to discontinue for gold seed insertion) * diagnosis of bleeding diathesis * large prostate with significant arch interference on trus after 3 months of neoadjuvant adt. * previous turp * poor baseline urinary function defined as international prostate symptom score (ipss) \>20 * significant medical co-morbidity rendering patient unsuitable for general anesthetic * no evidence of castrate resistance (defined as psa \< 3 ng/ml while testosterone is \< 0.7nmol/l. patients could have been on combined androgen blockade but are excluded if this was started due to psa progression. * definitive extrapelvic nodal or distant metastatic disease on staging investigations.
intrathecal morphine for thoracoscopic surgery

Conditions: Postoperative Pain

Summary: thoracic surgery is one of the surgeries where postoperative pain is intense. in this study, the investigators aimed to compare the efficacy of two different intrathecal morphine doses administered for postoperative analgesia according to patients' ideal body weight.

patients who underwent video-assisted thoracic surgery were divided into two groups: 10 mcg/kg and 7 mcg/kg intrathecal morphine for postoperative analgesia. intraoperative and postoperative hemodynamic variables, postoperative morphine consumption, postoperative pain scores, side effects and additional analgesic requiretment were recorded.

Eligibility criteria:
inclusion criteria: * \> 18 years old * asa class i and ii * video-assisted thoracoscopic surgery exclusion criteria: * \< 18 years old * asa class \> ii * serious hepatic, cardiac, renal, metabolic, endocrine diseases * coagulation disfunction * allergy to any of the study drugs * pneumonectomy * infection in the lumbar region

Keywords: postoperative analgesia pain score side effect morphine intrathecal
pain control with total knee replacement

Conditions: Postoperative Pain

Summary: the purpose of this project is to study the effects of gabapentin on pain control in the perioperative and post-operative period of total knee arthroplasty.

being able to understand and better control pain in patients undergoing total knee arthroplasty will help in many different areas of medicine. gabapentin is one pain control modality that has been used by many different orthopaedic surgeons with excellent retrospective results. gabapentin, however, has never been studied, to the investigators knowledge, in a prospective randomized fashion in the united states for total knee arthroplasty. this study will be the first of its kind to truly compare the effects of gabapentin, a drug that has been proven safe in many other areas of medicine, with placebo for total knee arthroplasty by analyzing post-operative narcotic usage, function and sleep quality.

Eligibility criteria:
inclusion criteria: * • age \> 25 years old * primary osteoarthritis of the knee * must be undergoing unilateral total knee arthroplasty * anesthesia assesment score i, ii, or iii exclusion criteria: * severe joint malalignment (defined as varus/valgus angle \> 20 deg) * use of gabapentin pre-operatively * history of chronic pain (currently under treatment) * history of substance abuse * impaired kidney function (defined as creatinine \> 1.5) * epilepsy (currently on medication for treatment) * known allergy to gabapentin * known history of depression or suicidal thoughts and behaviors * anyone who is not a candidate for general anesthesia or any other portion of the investigator's standard of care.
a novel probiotic mixture in adults with ibs

Conditions: Irritable Bowel Syndrome

Summary: irritable bowel syndrome (ibs) is faced by gastroenterologists on a daily basis and probiotics are a potential therapeutic tool, however, there is no strain recommendations. this multicenter re-al-world, single-arm, open-label study aims to assess the effectiveness, safety, and patient satis-faction of a novel probiotic mixture in patients with ibs. methods: this study is conducted by italian gastroenterologists who enroll patients with ibs. throughout the 8-week treatment (t1) period with a probiotic mixture (lactobacillus paracasei 101/37 lmg p-17504, lac-tobacillus plantarum 14d cect 4528, bifidobacterium breve bbr8 lmg p-17501, bifidobacterium breve bl10 lmg p-17500, and bifidobacterium animalis ssp. lactis bi1 lmg p-17502), participants complete a questionnaire to evaluate ibs symptoms at baseline, at the end of treatment, and after one-month follow-up (t2).

irritable bowel syndrome (ibs) is faced by gastroenterologists on a daily basis and probiotics are a potential therapeutic tool, however, there is no strain recommendations. this multicenter re-al-world, single-arm, open-label study aims to assess the effectiveness, safety, and patient satis-faction of a novel probiotic mixture in patients with ibs. methods: this study is conducted by italian gastroenterologists who enroll patients with ibs. throughout the 8-week treatment (t1) period with a probiotic mixture (lactobacillus paracasei 101/37 lmg p-17504, lac-tobacillus plantarum 14d cect 4528, bifidobacterium breve bbr8 lmg p-17501, bifidobacterium breve bl10 lmg p-17500, and bifidobacterium animalis ssp. lactis bi1 lmg p-17502), participants complete a questionnaire to evaluate ibs symptoms at baseline, at the end of treatment, and after one-month follow-up (t2).

Eligibility criteria:
inclusion criteria: * recurrent abdominal pain at least once per week during the past three months associated with two or more of the following criteria: * related to defecation, * associated with a change in the frequency of stool, * associated with a change in the appearance of stool. exclusion criteria: * none

Keywords: irritable bowel syndrome probiotics
varenicline for long-term nicotine replacement therapy (nrt) users

Conditions: Tobacco Dependence

Summary: primary aim: will varenicline be better than placebo to get long-term users of nrt to stop? secondary aim: to assess in details some side effects of varenicline i.e. nausea and abnormal dreams.

100-200 long-term users of nrt will be enrolled in a placebo, controlled, randomized trial with varenicline or placebo for 12 weeks to stop the use of nrt. assessments consist of carbon monoxide in expired air, p-cotinine, body-weight, questions about craving, nausea and dreams. primary result is percent not using nrt and not smoking at 12 weeks (point prevalence last 7 days) and secondary result is not smoking and not using nrt at 12 months. secondary aims, is a more detailed assessment of nausea and dreams; well-known side effects of varenicline and secondary results are a qualitative description of nausea and dreams.

Eligibility criteria:
inclusion criteria: * long-term, daily nrt users (except nicotine patch) (\>11 months) ex-smokers that are willing to try to stop the use of nrt and adhere to this protocol. * more than 4 pieces of nicotine gum/ sublingual tablets/ lozenges/ per day, or more than 3 inhaler cylinders per day, or * more than 10 puffs of nasal spray per day. exclusion criteria: * age \< 18 years, * co smokers, * pregnant and lactating women, * used varenicline before, * not able to cooperate, * other significant diseases that might influence the trial (such as moderate -severe cardiac disease, lung cancer,) in expired air \> 7 ppm.

Keywords: long term nicotine gum use varenicline adverse effects
study of prx302 for lower urinary tract symptoms due to benign prostatic hyperplasia (bph)

Conditions: Benign Prostatic Hyperplasia

Summary: the purpose of this study is to evaluate the safety, tolerability and efficacy of a single treatment of prx302 for the treatment of benign prostatic hyperplasia (bph) as compared to placebo.


Eligibility criteria:
inclusion criteria: * lower urinary tract symptoms (luts) attributable to bph for ≥6 months * written informed consent prior to enrollment in the study * ipss ≥12 * prostate volume of 30 - 100 ml as determined by trus * maximum urine flow (qmax) of 4 - 15 ml/sec * refractory, intolerant or refused the use of alpha-blockers and/or 5 alpha-reductase inhibitors * unwilling or unable to undergo conventional surgical or available minimally invasive treatments * blood psa values \<10 ng/ml exclusion criteria: * inability to void at least 125 ml of urine * pvr volume \>200 ml * presence of or history of certain conditions that could interfere with study results or endanger subject * use of certain prescribed medications that could interfere with study results

Keywords: benign prostatic hyperplasia bph enlarged prostate lower urinary tract symptoms (luts)
integrative therapy for holistic, natural cognition and lifestyle rehabilitation

Conditions: Cognitive Dysfunction

Summary: an observational study to determine outcomes of older adults who are under naturopathic medical care for cognitive complaints at a specific clinic in southern california.

this prospective observational study will examine patient outcomes associated with individualized, whole-system integrative medical care, provided by a naturopathic physician at a specific clinic in the state of california. participants will be older adult patients of the clinic who present with objectively measurable cognitive dysfunction, and who elect to voluntarily participate in the study. participants' cognitive function will be assessed using validated objective (nih toolbox) and subjective (nih neuro-quality of life questionnaires) instruments. the primary outcomes are change from baseline to six months post-baseline in these two instruments. additionally, physical activity and sleep data will be tracked using wearable telemetry, and neurophysiological parameters will be measured with electroencephalography. detailed treatment descriptions and adverse events will be tracked.

Eligibility criteria:
inclusion criteria: * community-dwelling adults ≥60 years of age. * montreal cognitive assessment (moca) score of 12-23. * able to independently make decisions. * able to safely travel to north county natural medicine for 4 study visits and approximately 4 clinical visits, for a duration of 6 months. * able to wear an oura ring, download data every 6 days, and keep the ring regularly charged for the duration of participants' involvement in the study. * a high school diploma or equivalent. * ability to communicate via email. * ability to independently fill out a computer-administered questionnaire. * ability to withhold from seeing another integrative or alternative medicine provider for the 6 months of participation in the study. exclusion criteria: * inability to read and write in english. * moca score \>23. * a visual impairment that would prevent reading a computer screen. * partial or full deafness. * a previous diagnosis of dementia (e.g. alzheimer's disease or any other kind of dementia). * congenital cognitive impairment or disability. * alcohol or substance abuse. * serious somatic disease, neurodegenerative disease, acute onset of cognitive decline, or rapid neurological impairment. * inability to bring an affiliate to the informed consent consultation.

Keywords: mild cognitive impairment (mci) cognitive decline alzheimer's disease (ad) dementia
risk factors for aneurysm rebleeding

Conditions: Subarachnoid Hemorrhage, Aneurysmal

Summary: the purpose of this study is to examine the risk factors for aneurysm rebleeding.

to investigate risk factors for spontaneous aneurysm rebleeding during hospitalization and to reach conclusions if any,of clinical signs for predicting rebleeding.

Eligibility criteria:
inclusion criteria: * individual whose clinical course was clear enough to be traced back and whose conservative treatment duration was shorter than 6 weeks was included exclusion criteria: * rebleeding patients with certain inducing factors such as: * severe emotional episode, * severe coughing, * constipation, * excessive activities, or * with coagulation disorder,or * with other intracranial vascular malformations,such as: * moyamoya disease, * arteriovenous malformation were excluded. * also patients who rebled while angiography were excluded.
computer cognitive training for post-acute covid-19 syndrome

Conditions: Corona Virus Infection; Cognitive Dysfunction

Summary: this study will assess the acceptability, feasibility, and impact of game-based computer-delivered cognitive training on cognitive function in persons with cognitive symptoms that persist after recovery from acute coronavirus-19 (covid) infection.

over the course of the past several years, it has become apparent that a number of individuals have residual symptoms after covid-19 infection after they have recovered from the acute phase of the illness (al-aly, xie, \& bowe, 2021; davis et al., 2021; greenhalgh, knight, a'court, buxton, \& husain, 2020; hewitt et al., 2021). the constellation of symptoms experienced by these individuals has been termed "post-acute covid syndrome" or pacs (nalbandian et al., 2021). a key part of helping affected individuals is supporting their efforts at self-management of these symptoms (national institute for health and care excellence, 2020; wade, 2020). although a diverse number of physical and psychological symptoms have been seen as sequelae of covid (davis et al., 2021), among the most troubling for patients have been difficulties in attention, concentration, working memory, and long-term memory, commonly referred to as "brain fog" (graham et al., 2021; hampshire et al., 2021; hewitt et al., 2021). in the proposed study, we will complete a pilot study of game-based cognitive training in persons with symptoms of long covid using a protocol that was useful and acceptable to participants in a previous study (ownby \& kim, 2021). we will explore participants' views on the cognitive training intervention, its effects on their perceived cognitive functioning, and assess the intervention's impact on participants' processing speed. we will also explore their preferences for type of cognitive training activity and the impact of information about memory functioning.

Eligibility criteria:
inclusion criteria: * persons with a history of covid-19 infection confirmed through screening of symptom pattern or testing and report of mental symptoms (difficulties in attention, memory, or executive functions such as coordinating two activities at once) more than 30 days after resolution of the initial acute infection. exclusion criteria: * cognitive or psychiatric conditions of a severity that precludes the person's ability to give informed consent for their participation or to attend and cooperate with assessment and training, as judged by the investigators.
validation of indirect calorimetry in children undergoing non-invasive ventilation

Conditions: Respiratory Insufficiency in Children; Noninvasive Ventilation; Nutrition Assessment

Summary: nutritional status in critically ill pediatric patients is considered a fundamental prognostic factor in terms of mortality, morbidity, complications and outcome. many studies report how predictive equations most commonly applied are inaccurate, therefore under or over estimating the body energy requirements. for this reason, actual measurement of resting energy expenditure (ree) through indirect calorimetry (ic) is considered to be a better approach. currently, ic is not validated during the use of non-invasive ventilation. aim of the present study is to validate the measurement of ree with ic in pediatric patients undergoing non-invasive ventilation through a single-limb circuit with intentional leak.


Eligibility criteria:
inclusion criteria: * children admitted to the pediatric intensive care unit who completed the weaning phase from non-invasive ventilation. * age ≤ 6 years * patients whose parents provided signed informed consent exclusion criteria: * age \> 6 years * patients whose parents didn't provide signed informed consent

Keywords: energy expenditure ventilator weaning calorimetry, indirect
beta-1,3/1,6-d-glucan ganoderma lucidum on ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the aim of this study is to determine the efficacy and safety of beta-1,3/1,6-d-glucan from mycelium extract of ganoderma lucidum on ulcerative colitis


Eligibility criteria:
inclusion criteria: * age ≥18 years old * ulcerative colitis patients who are treated by 5-aminosalicylic acid (5-asa) 3x500 mg * agreed to participate in this study exclusion criteria: * ulcerative colitis patients who are treated by corticosteroid, immunosuppressive agents and biologic agents * allergic to ganoderma lucidum * could not be randomised and participate in this study by clinical judgement

Keywords: beta-1,3/1,6-d-glucan ganoderma lucidum ulcerative colitis
progesterone levels and pregnancy results

Conditions: Pregnancy Complications; Pregnancy Preterm; Pregnancy Loss

Summary: the aim of this study is to evaluate the amniotic fluid and serum progesterone level and pregnancy outcome

studies have investigated the relationship between maternal serum progesterone level and low birth weight baby birth, hypertensive disorders of pregnancy, and early pregnancy bleeding. in some cases, patients are supported by oral or vaginal progesterone treatments during pregnancy. we also measure the relationship between maternal serum progesterone by measuring the level of amnion progesterone; we aimed to analyze the effects on pregnancy outcomes by observing preterm birth, premature rupture of membranes, low birth weight, baby gender, maternal problems that may occur during pregnancy, fetal problems.

Eligibility criteria:
inclusion criteria: * singleton pregnancy * women who did not receive progesterone treatment during pregnancy exclusion criteria: * women who receive progesterone treatment during pregnancy * multiple pregnancies * diagnosed hypertension, diabetes mellitus, kidney disease, heart disease, liver disease
a clinical study of two dentinal hypersensitivity treatments used with normal oral hygiene

Conditions: Dentin Sensitivity

Summary: this study will compare the safety and effectiveness of normal oral hygiene with two different marketed dentifrices, on longer term dentinal hypersensitivity response following use of potassium oxalate desensitizers.


Eligibility criteria:
inclusion criteria: * be at least 18 years of age * provide written informed consent prior to participation and be given a signed copy of the informed consent form * complete a confidentiality disclosure agreement * be in good general health as determined by the investigator/designee * have at least one tooth with a schiff sensitivity score of at least 1 in response to the air challenge. exclusion criteria: * self-reported pregnancy or nursing * severe periodontal disease, as characterized by purulent exudate, generalized mobility, and/or severe recession * active treatment of periodontitis * fixed facial orthodontic appliances * a history of kidney stones * known allergies to the following ingredients; aqua, glycerin, cellulose gum, dipotassium oxalate, carbomer, sodium hydroxide, sodium benzoate, and potassium sorbate * any diseases or conditions that might interfere with the safe completion of the study * an inability to undergo any study procedures.

Keywords: sensitivity
long term follow-up study for patients enrolled on the bp-004 clinical study

Conditions: Acute Lymphoblastic Leukemia; Leukemia, Acute Myeloid (AML), Child; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Primary Immunodeficiency; Anemia, Aplastic; Hemoglobinopathies; Cytopenia; Fanconi Anemia; Diamond Blackfan Anemia; Thalassemia; Anemia, Sickle Cell

Summary: this is a long-term follow up study evaluating the safety of bpx-501 t cells (rivogenlecleucel) and infused in pediatric patients previously enrolled on the bp-004 study.

subjects enrolled on the bp-004 study who have completed or discontinued from the study, and are beyond day 180 will be requested to enroll on this long-term follow up protocol. long term follow up for gene therapy clinical and safety endpoints will continue up to 15 years.

Eligibility criteria:
inclusion criteria: * signed written informed consent by the patient or the patient's guardian for children who are minors * enrolled on bp-004 protocol, received bpx-501 infusion, completed or discontinued from the study, and are beyond day +180. exclusion criteria: * lack of parents'/guardian's informed consent for children who are minors * loss of allograft prior to 6 months

Keywords: long term follow up gene-modified cells all aml hematologic neoplasms hematologic malignancies anemia congenital cytopenia primary immune deficiencies hemoglobinopathy
a study comparing the efficacy of an alpha blocker versus an alpha blocker plus solifenacin in men with overactive bladder

Conditions: Urinary Bladder, Overactive

Summary: the purpose of this study is to explore additional benefit of solifenacin after 12-week treatment, compared with alpha blocker monotherapy in men with residual oab symptoms.


Eligibility criteria:
inclusion criteria: * persistent symptoms of oab as verified by the 3 day voiding diary, defined by: * symptoms of urinary urgency (defined as a level of \>=3 in a 5 point urgency scale) at least two episode per 24 hours and * symptoms of urinary frequency ( \>8 micturitions per 24 hours) * on a stable dose of tamsulosin for at least 1 month exclusion criteria: * previous history of acute urinary retention * patients have a baseline post-void residual (pvr) which exceeded 50% of voided urine volume * any condition that is a contraindication for anticholinergic treatment, including uncontrolled narrow-angled glaucoma, urinary retention or gastric retention * symptomatic acute urinary tract infection (uti) during the screening period * treatment within the 14 days preceding randomization, or expected to initiate treatment during the study with any anticholinergic drugs and drug treatment for overactive bladder * a 5-alpha reductase inhibitor if started less than 3 months prior to screening * patients with previous urethral, prostate or bladder neck surgery

Keywords: alpha blocker tamsulosin solifenacin overactive bladder urgency incontinence